Board meeting on 26 October 2026 to approve unaudited results for quarter and half year ended 30 September 2026
Board meeting called for Monday, 26 October 2026.
By ScoutQuest · · 2 min read
- Board Meeting Date
- Monday, 26 October 2026
- Agenda
- standalone and consolidated unaudited results for the quarter and half year ended 30 September 2026
- Trading Window Closure
- closed from 1 October 2026, to stay closed till 48 hours after the results are declared
What the company has told the exchanges
The update is a board meeting intimation. Eris Lifesciences has informed BSE and NSE that a meeting of its Board of Directors is scheduled on Monday, 26 October 2026. The main stated purpose is to consider and approve the company's standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2026.
What exactly will be placed before the board
- The standalone unaudited financial results for the quarter and half year ended 30 September 2026.
- The consolidated unaudited financial results for the same period, which combine the company with its subsidiaries and give the group-level picture.
The update says the board will consider these "inter alia", which means the results are one of the items on the agenda and other board matters may also be taken up.
Why the period matters
These results cover the three months from July to September 2026, along with the six-month period ending on that date. A half-yearly statement shows how the first two quarters have together performed, which is often more useful than a single quarter for spotting a trend.
Trading window
The company has said its trading window has already been closed from 1 October 2026. It will remain closed until 48 hours after the financial results are declared. During this window, designated persons of the company and their immediate relatives are restricted from dealing in the company's shares. This is a routine restriction that runs around the time results are prepared and announced.
How to read this announcement
A board meeting intimation is a scheduling notice rather than a statement of performance. It tells you when the numbers will be considered and approved by the board, which is normally just before they are released to the exchanges. The actual figures, and the commentary around them, come in the results update itself.
What to look for when the results are out
- The standalone numbers, which reflect the company on its own.
- The consolidated numbers, which show the group including subsidiaries, and can differ meaningfully from the standalone picture.
- The comparison with the same period a year earlier and with the preceding quarter, so that growth or a slowdown can be judged.
- Any commentary the company gives alongside the numbers on the half-year performance.
In short, this notice sets the date on which the July to September 2026 numbers will be taken up by the board, and confirms the share dealing restriction that applies until 48 hours after those results are declared.
Also from Eris Lifesciences
Eris Lifesciences schedules Q2 & H1 FY2027 earnings call for October 26, 2026 at 4:30 PM IST
19 Oct 2026
Board meet on 26 October 2026 to approve September quarter and half year results
19 Oct 2026
More numbers
- Trading window stays closed after results are declared48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.